Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | Belfast Health & Social Care Trust |
| Main Category: | Goods |
| Procurement Method: | Direct award |
| Method Rationale: | Schedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development. Age-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget. An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson's), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections. The study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care. To 'blind' this clinical trial (to reduce bias) requires the development, manufacture and testing of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise. |
All 3 notices for this procurement, oldest first.
Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial
Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial.
Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to
| Award status: | Active |
This procurement is for the manufacture and testing of over encapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial
Published contracts in the last 12 months
189
total contracts
£110.4m
total value
£13,803,922
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Tender Status: | Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 21 January 2026 |
| Application Deadline: | — |
| Procurement ID (OCID): | ocds-h6vhtk-05f108 |
| Notice Reference: | 005092-2026 |